Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis

Summary

Post-thrombotic syndrome (PTS) is a common complication of deepvein thrombosis (DVT). Poor quality treatment with vitamin K antagonists (VKA) is a risk factor for PTS. We hypothesised that treatment with the direct oral anticoagulant (DOAC) rivaroxaban may lower PTS incidence as compared to enoxaparin/VKA, as DOACs have a more stable pharmacologic profile than VKA. We performed a post-hoc subgroup analysis of the Einstein DVT trial (n=3449). Kaplan-Meier survival analysis was performed to compare the cumulative incidence of PTS between the rivaroxaban and enoxaparin/VKA groups. Hazard ratios (HR) and 95 % confidence intervals (CI) were calculated using Cox proportional hazards models. We included 336 patients with a mean age of 58 ± 16 years and a median follow-up after index DVT of 57 months (interquartile range 48–64). Of these, 162 (48 %) had been treated with rivaroxaban and 174 (52 %) with enoxaparin/VKA. The cumulative PTS incidence at 60 months follow-up was 29 % in the rivaroxaban group and 40 % in the enoxaparin/VKA group. After adjusting for age, gender, body mass index, previous VTE, ipsilateral recurrent DVT, extent of DVT, idiopathic DVT, duration of anticoagulant treatment, compliance to assigned study medication, elastic compression stocking use and active malignancy, the HR of PTS development for rivaroxaban was 0.76 (95 % CI: 0.51–1.13). In conclusion, treatment of acute DVT with rivaroxaban was associated with a numerically lower but statistically non-significant risk of PTS compared to enoxaparin/VKA treatment. The potential effect on reducing PTS deserves evaluation in a large randomised trial.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

Post-thrombotic syndrome - rivaroxaban - vitamin K antagonists - deep-vein thrombosis

^* The participating centres and investigators are listed in the Suppl. Material.

• References

• 1 Prandoni P, Kahn SR.. Post-thrombotic syndrome: prevalence, prognostication and need for progress. Br J Haematol 2009; 145: 286-295.
• 2 Kahn SR, Shrier I, Julian JA. et al. Determinants and time course of the post-thrombotic syndrome after acute deep venous thrombosis. Ann Intern Med 2008; 149: 698-707.
• 3 Prandoni P, Villalta S, Bagatella P. et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica 1997; 82: 423-428.
• 4 Brandjes DP, Buller HR, Heijboer H. et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997; 349: 759-762.
• 5 Pesavento R, Villalta S, Prandoni P.. The postthrombotic syndrome. Intern Emerg Med 2010; 05: 185-192.
• 6 Strandness DE, Langlois Y, Cramer M. et al. Long-term sequelae of acute venous thrombosis. J Am Med Assoc 1983; 250: 1289-1292.
• 7 Prandoni P, Lensing AW, Prins MH. et al. The impact of residual thrombosis on the long-term outcome of patients with deep venous thrombosis treated with conventional anticoagulation. Semin Thromb Hemost 2015; 41: 133-140.
• 8 The Colombus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337: 657-662.
• 9 Chitsike RS, Rodger MA, Kovacs MJ. et al. Risk of post-thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: results from the REVERSE study. J Thromb Haemost 2012; 10: 2039-2044.
• 10 Mearns ES, Kohn CG, Song JS. et al. Meta-analysis to assess the quality of international normalized ratio control and associated outcomes in venous thromboembolism patients. Thromb Res 2014; 134: 310-319.
• 11 van Dongen CJ, Prandoni P, Frulla M. et al Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome. J Thromb Haemost 2005; 03: 939-942.
• 12 Hull RD, Liang J, Townshend G.. Long-term low-molecular-weight heparin and the post-thrombotic syndrome: a systematic review. Am J Med 2011; 124: 756-765.
• 13 The Einstein Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
• 14 Kahn SR, Partsch H, Vedantham S. et al. Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Definition of post-thrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardisation. J Thromb Haemost 2009; 07: 879-883.
• 15 Barbosa CD, Balp MM, Kulich K. et al. A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient preference and adherence 2012; 06: 39-48.
• 16 Prandoni P, Lensing AW, Prins MH. et al. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med 2004; 141: 249-256.
• 17 Kahn SR, Shapiro S, Wells PS. et al. Compression stockings to prevent postthrombotic syndrome: a randomised placebo-controlled trial. Lancet 2014; 383: 880-888.